Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to the research and development of novel treatments for autoimmune diseases. Operating as a subsidiary of Roivant Sciences, the company's core focus is on anti-FcRn (neonatal Fc receptor) inhibitor technology. Its pipeline is centered around two primary product candidates: batoclimab (IMVT-1401) and IMVT-1402. Both are fully human monoclonal antibodies designed to selectively bind to and inhibit the FcRn pathway, thereby reducing the levels of pathogenic immunoglobulin G (IgG) autoantibodies that drive various autoimmune conditions.
As a pre-revenue, clinical-stage entity, Immunovant does not currently generate product sales and relies on capital markets and its parent company for funding. The company is advancing its candidates through multiple clinical trials across several indications, including myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves' disease, and cutaneous lupus erythematosus. Immunovant operates in a highly competitive landscape, contending with other biotechnology and pharmaceutical firms developing FcRn-targeting therapies, such as argenx and UCB. The company's strategic direction is heavily integrated with Roivant Sciences, which maintains significant operational involvement and strategic oversight over its clinical programs.
